ArticleThe oncologist2023

Using the HER2/CEP17 FISH Ratio to Predict Pathologic Complete Response Following Neoadjuvant Anti-HER2 Doublet Therapy in HER2+ Breast Cancer.

Eric M Lander et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.